tradingkey.logo

Eton Pharmaceuticals Inc

ETON
16.830USD
-0.160-0.94%
收盘 12/26, 16:00美东报价延迟15分钟
451.34M总市值
亏损市盈率 TTM

Eton Pharmaceuticals Inc

16.830
-0.160-0.94%

关于 Eton Pharmaceuticals Inc 公司

Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.

Eton Pharmaceuticals Inc简介

公司代码ETON
公司名称Eton Pharmaceuticals Inc
上市日期Nov 09, 2018
CEOBrynjelsen (Sean E)
员工数量31
证券类型Ordinary Share
年结日Nov 09
公司地址21925 W Field Pkwy Ste 235
城市DEER PARK
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编60010-7278
电话18477877361
网址https://etonpharma.com/
公司代码ETON
上市日期Nov 09, 2018
CEOBrynjelsen (Sean E)

Eton Pharmaceuticals Inc公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Sean E. Brynjelsen
Mr. Sean E. Brynjelsen
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
864.94K
-19.54%
Mr. Charles J. (Chuck) Casamento
Mr. Charles J. (Chuck) Casamento
Independent Director
Independent Director
93.42K
--
Mr. Paul V. Maier
Mr. Paul V. Maier
Independent Director
Independent Director
84.75K
--
Dr. Norbert G. Riedel, Ph.D.
Dr. Norbert G. Riedel, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
84.75K
-54.72%
Mr. James R. Gruber
Mr. James R. Gruber
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
21.71K
-34.20%
Ms. Ipek Erdogan-Trinkaus
Ms. Ipek Erdogan-Trinkaus
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. David C. Krempa
Mr. David C. Krempa
Chief Business Officer
Chief Business Officer
--
--
Ms. Jennifer (Jenn) Adams
Ms. Jennifer (Jenn) Adams
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Sean E. Brynjelsen
Mr. Sean E. Brynjelsen
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
864.94K
-19.54%
Mr. Charles J. (Chuck) Casamento
Mr. Charles J. (Chuck) Casamento
Independent Director
Independent Director
93.42K
--
Mr. Paul V. Maier
Mr. Paul V. Maier
Independent Director
Independent Director
84.75K
--
Dr. Norbert G. Riedel, Ph.D.
Dr. Norbert G. Riedel, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
84.75K
-54.72%
Mr. James R. Gruber
Mr. James R. Gruber
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
21.71K
-34.20%
Ms. Ipek Erdogan-Trinkaus
Ms. Ipek Erdogan-Trinkaus
Chief Commercial Officer
Chief Commercial Officer
--
--

收入明细

FY2025Q2
FY2025Q1
FY2024
由于公司未披露,未能获取相关数据
地区USD
名称
营收
占比
United States
18.93M
0.00%
业务
地区
由于公司未披露,未能获取相关数据

股东统计

更新时间: 11月17日 周一
更新时间: 11月17日 周一
持股股东
股东类型
持股股东
持股股东
占比
Opaleye Management Inc.
10.66%
EcoR1 Capital, LLC
7.57%
BlackRock Institutional Trust Company, N.A.
5.82%
The Vanguard Group, Inc.
5.01%
Nantahala Capital Management, LLC
4.38%
其他
66.55%
持股股东
持股股东
占比
Opaleye Management Inc.
10.66%
EcoR1 Capital, LLC
7.57%
BlackRock Institutional Trust Company, N.A.
5.82%
The Vanguard Group, Inc.
5.01%
Nantahala Capital Management, LLC
4.38%
其他
66.55%
股东类型
持股股东
占比
Hedge Fund
21.89%
Investment Advisor
21.61%
Investment Advisor/Hedge Fund
16.73%
Research Firm
5.68%
Individual Investor
4.30%
Bank and Trust
0.10%
Venture Capital
0.09%
Pension Fund
0.06%
Insurance Company
0.04%
其他
29.50%

机构持股

更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
197
16.82M
61.06%
-98.00
2025Q3
198
16.82M
61.07%
+73.58K
2025Q2
187
16.74M
59.55%
+2.45M
2025Q1
147
14.23M
51.82%
+331.79K
2024Q4
120
13.23M
40.20%
+3.64M
2024Q3
91
9.60M
36.18%
+1.31M
2024Q2
87
8.28M
33.62%
+960.54K
2024Q1
87
7.24M
33.51%
-1.37M
2023Q4
89
7.16M
31.90%
+250.49K
2023Q3
92
6.91M
28.21%
+911.27K
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
Opaleye Management Inc.
2.86M
10.66%
+7.93K
+0.28%
Jun 30, 2025
EcoR1 Capital, LLC
2.03M
7.57%
+91.26K
+4.71%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
1.40M
5.22%
+1.08M
+334.29%
Jun 30, 2025
The Vanguard Group, Inc.
1.31M
4.89%
+211.21K
+19.18%
Jun 30, 2025
Nantahala Capital Management, LLC
1.18M
4.38%
--
--
Jun 30, 2025
Brynjelsen (Sean E)
864.94K
3.23%
-210.00K
-19.54%
Jun 05, 2025
Geode Capital Management, L.L.C.
592.87K
2.21%
+294.62K
+98.78%
Jun 30, 2025
Westside Investment Management, LLC
472.79K
1.76%
-20.86K
-4.23%
Jun 30, 2025
Morgan Stanley & Co. LLC
311.99K
1.16%
+186.23K
+148.08%
Jun 30, 2025
查看更多

持股ETF

更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
First Trust Active Factor Small Cap ETF
0.11%
iShares Micro-Cap ETF
0.09%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.07%
Vanguard US Momentum Factor ETF
0.06%
iShares Russell 2000 Growth ETF
0.03%
ProShares Hedge Replication ETF
0.02%
Global X Russell 2000 ETF
0.02%
Proshares Ultra Russell 2000
0.02%
iShares Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
查看更多
First Trust Active Factor Small Cap ETF
占比0.11%
iShares Micro-Cap ETF
占比0.09%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
占比0.07%
Vanguard US Momentum Factor ETF
占比0.06%
iShares Russell 2000 Growth ETF
占比0.03%
ProShares Hedge Replication ETF
占比0.02%
Global X Russell 2000 ETF
占比0.02%
Proshares Ultra Russell 2000
占比0.02%
iShares Russell 2000 ETF
占比0.01%
ProShares UltraPro Russell2000
占比0.01%

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据

常见问题

Eton Pharmaceuticals Inc的前五大股东是谁?

Eton Pharmaceuticals Inc 的前五大股东如下:
Opaleye Management Inc.持有股份:2.86M,占总股份比例:10.66%。
EcoR1 Capital, LLC持有股份:2.03M,占总股份比例:7.57%。
BlackRock Institutional Trust Company, N.A.持有股份:1.40M,占总股份比例:5.22%。
The Vanguard Group, Inc.持有股份:1.31M,占总股份比例:4.89%。
Nantahala Capital Management, LLC持有股份:1.18M,占总股份比例:4.38%。

Eton Pharmaceuticals Inc的前三大股东类型是什么?

Eton Pharmaceuticals Inc 的前三大股东类型分别是:
Opaleye Management Inc.
EcoR1 Capital, LLC
BlackRock Institutional Trust Company, N.A.

有多少机构持有Eton Pharmaceuticals Inc(ETON)的股份?

截至2025Q4,共有197家机构持有Eton Pharmaceuticals Inc的股份,合计持有的股份价值约为16.82M,占公司总股份的61.06%。与2025Q3相比,机构持股有所增加,增幅为-0.01%。

哪个业务部门对Eton Pharmaceuticals Inc的收入贡献最大?

在FY2025Q2,--业务部门对Eton Pharmaceuticals Inc的收入贡献最大,创收--,占总收入的--%。
KeyAI